Advertisement
ResearchIn-Press PreviewAutoimmunityImmunology
Open Access | 10.1172/JCI187862
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by Hughes, E. in: JCI | PubMed | Google Scholar
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by Syage, A. in: JCI | PubMed | Google Scholar
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by Mirzaei Mehrabad, E. in: JCI | PubMed | Google Scholar
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by Lane, T. in: JCI | PubMed | Google Scholar
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by Spike, B. in: JCI | PubMed | Google Scholar
1Department of Pathology, University of Utah School of Medicine, Salt Lake City, United States of America
2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, United States of America
3Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, United States of America
Find articles by
Tantin, D.
in:
JCI
|
PubMed
|
Google Scholar
|
Published April 29, 2025 - More info
Stem-like T cells selectively contribute to autoimmunity, but the activities that promote their pathogenicity are incompletely understood. Here, we identify the transcription coregulator OCA-B as a driver of the pathogenic maturation of stem-like CD4+ T cell to promote autoimmune demyelination. Using two human multiple sclerosis (MS) datasets, we show that POU2AF1, the gene encoding OCA-B, is elevated in CD4+ T cells from MS patients. We show that T cell-intrinsic OCA-B loss protects mice from experimental autoimmune encephalomyelitis (EAE) while preserving responses to viral CNS infection. In EAE models driven by antigen reencounter, OCA-B deletion nearly eliminates CNS infiltration, proinflammatory cytokine production and clinical disease. OCA-B-expressing CD4+ T cells of mice primed with autoantigen express an encephalitogenic gene program and preferentially confer disease. In a relapsing-remitting EAE model, OCA-B loss protects mice specifically at relapse. During remission, OCA-B promotes the expression of Tcf7, Slamf6, and Sell in proliferating CNS T cell populations. At relapse timepoints, OCA-B loss results in both the accumulation of an immunomodulatory CD4+ T cell population expressing Ccr9 and Bach2, and loss of pro-inflammatory gene expression from Th17 cells. These results identify OCA-B as a driver of pathogenic CD4+ T cells.